CompletedNot Applicable

Impact of a Pharmacovigilance Program Led by Advanced Practice Nursing

Spain395 participantsStarted 2022-05-01

Plain-language summary

HYPOTHESIS An advanced practice nursing intervention in the area of pharmacovigilance performed on patients and professionals improves the identification and reporting of suspected adverse drug reactions (ADR) and improves the overall experience of hospitalized patients.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients with pharmacological treatment.
. Patients of both sexes aged between 0 and 100 years.
. Patients admitted to medical or surgical hospitalization units or emergency services for at least 24 hours.
. Patients who have received the information and agreed to participate in the study.

Exclusion criteria

. Patients included in other clinical trials or drug studies at the time of selection.
. Patients with significant cognitive impairment, without adequate family support or primary caregiver.
. Patients and/or caregivers who, once offered to participate in the study, do not give their consent
. Impossibility of communication due to language barriers or other biopsychosocial problems.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Adverse drug event

Timeframe: Seven months

Trial details

NCT IDNCT05402254

SponsorNatalia Rodriguez Galan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-11-01

View on ClinicalTrials.gov More Adverse Drug Event trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients with pharmacological treatment.
. Patients of both sexes aged between 0 and 100 years.
. Patients admitted to medical or surgical hospitalization units or emergency services for at least 24 hours.
. Patients who have received the information and agreed to participate in the study.

Exclusion criteria

. Patients included in other clinical trials or drug studies at the time of selection.
. Patients with significant cognitive impairment, without adequate family support or primary caregiver.
. Patients and/or caregivers who, once offered to participate in the study, do not give their consent
. Impossibility of communication due to language barriers or other biopsychosocial problems.